GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)
Launched by SHANGHAI 10TH PEOPLE'S HOSPITAL · May 3, 2021
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female aged 18- 45;
- • Meet 2003 Rotterdam criteria;
- • overweight/obesity,BMI≥24kg/m2.
- Exclusion Criteria:
- • any contraindication to dulaglutide (known or suspected hypersensitivity to dulaglutide or related products, previous acute pancreatitis or chronic pancreatitis, inflammatory bowel disease; personal history or family history of medullary thyroid carcinoma, or personal history of multiple endocrine neoplasia type 2)；
- • treatment with any other drugs that may interfere with the trial, including traditional Chinese medicine, contraceptives, metformin, GLP-1RA or pioglitazone within the last 3 months；
- • chronic kidney disease or severe liver dysfunction；
- • malignant tumors；
- • mental illness;
- • pregnancy or lactation；
- • inflammatory bowel disease;
- • recent participation in other weight-loss research projects within the last 3 months.
About Shanghai 10th People's Hospital
Shanghai 10th People's Hospital, affiliated with Tongji University, is a leading clinical research institution in China known for its commitment to advancing medical science and improving patient care. With a focus on innovative therapies and cutting-edge research methodologies, the hospital conducts a wide range of clinical trials across various medical disciplines. Its state-of-the-art facilities and multidisciplinary team of experts enable rigorous study designs and high-quality data collection, fostering collaboration with both national and international partners. The hospital is dedicated to upholding ethical standards and promoting patient safety, ensuring that its clinical trials contribute significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Shen Qu, Dr
Study Chair
Shanghai 10th People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials